ecrin-mdr-crcClinical2012Metastatic colorectal cancerMetastatic Colorectal CancerInterventionalhttps://newmdr.ecrin.org/Study/2624252Japan6ECRIN MDRCompletedfalseRandomized Phase II Study of BSC vs Cetuximab vs Irinotecan and Cetuximab in Patients with KRAS codon G13D mutant Metastatic Colorectal Cancer (G13 study)Interventions: Cetuximab Cetuximab+Irinotecan BSC Primary outcome(s): Progression Free Survival Study Design: Parallel Randomized2012-06-152624252JPRN-UMIN000008850